Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting...
Source: businessinsider.com